Observe Medical ASA – Primary insider notice
Reference is made to the ongoing rights issue of 4,090,909 new shares (the "Offer Shares") at a subscription price of NOK 11.00 per share in Observe Medical ASA (the "Company") as announced in the Company's stock exchange announcement on 19 June 2020 (the "Rights Issue").
Primary insider, Kathrine Gamborg Andreassen, a member of the Company's board of directors, has today, on 30 June 2020, through her wholly-owned company Soleglad Invest AS, sold 144,428 subscription rights to subscribe for Offer Shares in the Rights Issue at a price of NOK 1.60 per subscription right.
Following the sale of the subscription rights, Kathrine Gamborg Andreassen, with related parties, holds no subscription rights to subscribe for Offer Shares in the Rights Issue and a total of 541,668 shares and 125,000 options in the Company.
This information is subject to disclosure requirements pursuant to section 4-2 of the Norwegian Securities Trading Act.
Mentice Appoints Thanos Karras as Americas General Manager to Accelerate Group’s Growth Strategy
Gothenburg, Sweden Mentice AB (STO: MNTC) today announced the appointment of Thanos Karras as the company’s new General Manager for Americas. Thanos’ appointment will play a critical role in supporting Mentice’s continual growth strategy and will help accelerate its leadership position in high fidel...
Observe Medical ASA – Last day of trading in subscription rights
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE AP...
Observe Medical ASA: Annual General Meeting held
Observe Medical ASA has today, June 30, 2020, held the Annual General Meeting. All resolutions were made in accordance with the board's and the nomination committee's proposals. The minutes from the general meeting is attached hereto and will also be available at www.observemedical.com....
Covid-19 delays short term revenue, while the commercial launch of IRRAflow and Hummingbird progresses
Normal business operations and short-term revenue impacted by covid-19 pandemic and associated restrictions In spite of covid-19 challenges, forward progress shown with global commercial product launches First European patients treated with IRRAflow after CE Mark recertification IRRAflow capita...